Bridgebio Pharma Executive and Leadership Team

Thomas Trimarchi, the President & Chief Financial Officer at BridgeBio Pharma, guides the company's financial strategy and overall corporate direction. Trimarchi oversees all financial operations, including capital allocation, investor relations, and financial planning, ensuring the fiscal health and sustainable growth of the organization. This leadership position involves managing the financial resources necessary to discover, develop, and deliver transformative medicines for genetic diseases and cancers. The President & Chief Financial Officer plays a crucial part in securing funding for late-stage clinical trials and commercialization efforts, directly impacting the company's ability to reach patients. By maintaining robust financial discipline and strategic foresight, Thomas Trimarchi enables BridgeBio Pharma to pursue its mission effectively and expand its portfolio of life-changing therapies.

Julie Everett, the Chief Operating Officer, Skeletal Dysplasias at BridgeBio Pharma, spearheads the operational execution for programs targeting skeletal dysplasias. Everett manages the day-to-day operations critical to advancing treatments like low-dose infigratinib for achondroplasia. This role involves coordinating cross-functional teams, ensuring seamless execution of clinical development plans, and optimizing resource allocation to meet strategic objectives. The Chief Operating Officer, Skeletal Dysplasias, works closely with research and development to translate scientific findings into viable therapeutic candidates. By driving operational excellence within this specific therapeutic area, Julie Everett directly contributes to BridgeBio Pharma's commitment to developing and delivering transformative medicines for patients suffering from rare genetic conditions, ensuring efficient progress through clinical trials and toward market availability.

Jesper Jernelius, the Chief Technology Officer at BridgeBio Pharma, directs the overarching technology strategy and innovation pipeline. Overseeing the integration of advanced technological solutions, Jernelius ensures that the company's digital infrastructure and research platforms support the rapid development of novel therapeutics. This leadership involves driving advancements in data analytics and computational biology to accelerate drug discovery and optimize clinical trial processes. By fostering a culture of technological excellence, Jernelius enables the efficient translation of scientific breakthroughs into tangible treatment options for patients with genetic diseases and cancers. The Chief Technology Officer's focus remains on leveraging cutting-edge technology to enhance operational efficiency and scientific rigor across all development stages, directly supporting BridgeBio Pharma's mission to deliver transformative medicines.

Ricardo Panicucci, the Chief Technology Officer, CMC at BridgeBio Pharma, directs the Chemistry, Manufacturing, and Controls strategy for the company's therapeutic pipeline. Panicucci oversees the development and scaling of manufacturing processes, ensuring the quality, safety, and consistency of drug candidates like AG10 and BBP-631. This critical role involves implementing advanced manufacturing technologies and robust quality systems to support clinical trials and eventual commercial supply. The Chief Technology Officer, CMC, collaborates closely with research and development teams to ensure that drug products are manufactured efficiently and meet stringent regulatory requirements. By driving innovation in CMC operations, Ricardo Panicucci ensures that BridgeBio Pharma can reliably produce transformative medicines, enabling the company to effectively treat patients suffering from genetic diseases and cancers.